Aktienanalyse zu Legend Biotech Corp (LEGN)LEGNLegend Biotech Corp

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Legend Biotech Corp is currently a hold. The stock is priced at $19.27, which is significantly lower than the average analyst price target of $56, indicating potential upside. However, the stock has a negative forward P/E of 27.55 and a year-to-date change of -10.41%, suggesting ongoing challenges. The recent appointment of a new CEO and a strong Q2 profit of $33.2 million, up from a loss of $125.4 million a year ago, are positive signs, but risks remain due to the stock's volatility and mixed analyst sentiments.